Cardioprotective Empagliflozin for Cancer Patients Receiving Doxorubicin (NCT06103279) | Clinical Trial Compass
UnknownPhase 2/3
Cardioprotective Empagliflozin for Cancer Patients Receiving Doxorubicin
40 participantsStarted 2023-11
Plain-language summary
Doxorubicin induced cardiomyopathy is the most common and serious side effect associated with doxorubicin treatment in cancer patients receiving doxorubicin. Studies have been shown that Empagliflozin can reduce cardiovascular mortality and hospitalization for heart failure in patients with heart failure with or without diabetes and current clinical trials indicate that SGLT2 inhibitors protect against heart failure outcomes and can reduce cardiac remodeling even in patients without diabetes. Empagliflozin had beneficial effects on the outcome of the cardiomyopathy and also has anti-tumor activity in animal studies, but clinical studies are still lacking. We are going to investigate the cardioprotective effect of Empagliflozin against doxorubicin induced cardiomyopathy.
Objective:
* Evaluate the prophylactic effect of using Empagliflozin "a selective inhibitor of the sodium glucose co-transporter 2 (SGLT2)" against doxorubicin induced cardiotoxicity in patients receiving doxorubicin-based chemotherapy.
* Monitor the safety of adding empagliflozin to doxorubicin-based chemotherapy.
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Chemo-naive patients with a first diagnosis of cancer and indication for first-line therapy with doxorubicin-based chemotherapy.
✓. Patients intended to receive at least 4 cycles of doxorubicin or greater.
✓. No previous cardiac conditions (including ischemic heart disease and clinically important congenital or acquired valvular and myocardial diseases) and taking no cardiac-related drugs.
✓. An echocardiographic LVEF value ≥55%.
✓. Normal hepatic and renal function (bilirubin ≤1.5 mg/dL, creatinine ≤2.0 mg/dL).
✓. ECOG performance grade 0, 1 or 2.
Exclusion criteria
✕. Hypersensitivity / Allergy to Empagliflozin.
✕. Any condition that contraindicates chemotherapy (i.e., pregnancy, lactation).
✕. New-onset cardiac symptoms or presence of congestive heart failure symptoms or established (dilated, restrictive or hypertrophic) cardiomyopathy, coronary heart disease, moderate or severe aortic and/or mitral valve disease or atrial fibrillation detected by baseline echocardiography.
What they're measuring
1
''Cardiac troponin T''
Timeframe: Baseline and one time at the end of chemotherapy (3 to 5 days after the last dose of doxorubicin).
2
Echocardiography (ECHO)
Timeframe: Baseline, after each 3 doses of doxorubicin-based chemotherapy and 3 months after the end of chemotherapy.